[HTML][HTML] Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
…, M Brun, F Le Maulf, M Girard… - … England Journal of …, 2014 - Mass Medical Soc
Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …
[HTML][HTML] Nintedanib for systemic sclerosis–associated interstitial lung disease
…, MD Mayes, G Raghu, W Sauter, M Girard… - … England Journal of …, 2019 - Mass Medical Soc
Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the …
…, M Gahlemann, E Clerisme-Beaty, M Girard… - The Lancet …, 2021 - thelancet.com
Background In the Safety and Efficacy of Nintedanib in Systemic Sclerosis (SENSCIS) trial,
nintedanib reduced the rate of decline in forced vital capacity (FVC) in patients with systemic …
nintedanib reduced the rate of decline in forced vital capacity (FVC) in patients with systemic …
OP0017 NINTEDANIB REDUCED DECLINE IN FORCED VITAL CAPACITY ACROSS SUBGROUPS OF PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED …
…, A Fischer, M Mayes, G Raghu, W Sauter, M Girard… - 2019 - ard.bmj.com
Background In the SENSCIS trial, nintedanib reduced the progression of interstitial lung
disease associated with systemic sclerosis (SSc-ILD) compared with placebo, as demonstrated …
disease associated with systemic sclerosis (SSc-ILD) compared with placebo, as demonstrated …
FRI0301 GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED …
…, A Fischer, M Mayes, G Raghu, W Sauter, M Girard… - 2019 - ard.bmj.com
Background In patients with idiopathic pulmonary fibrosis (IPF), nintedanib has a manageable
adverse event (AE) profile characterised predominantly by gastrointestinal (GI) events. …
adverse event (AE) profile characterised predominantly by gastrointestinal (GI) events. …
Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
…, M Kuwana, TM Maher, MD Mayes, G Raghu, M Girard… - 2019 - Eur Respiratory Soc
Background: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of
decline in FVC (mL/year) over 52 weeks vs placebo (primary endpoint). Aims: To assess …
decline in FVC (mL/year) over 52 weeks vs placebo (primary endpoint). Aims: To assess …
Sensitivity analyses from the INPULSIS™ trials of nintedanib
…, HR Collard, S Stowasser, M Girard… - European …, 2014 - Eur Respiratory Soc
Background: Nintedanib, an intracellular inhibitor of tyrosine kinases, is in development for
the treatment of idiopathic pulmonary fibrosis (IPF). The INPULSIS™ trials were two replicate, …
the treatment of idiopathic pulmonary fibrosis (IPF). The INPULSIS™ trials were two replicate, …
Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)
…, A Fischer, TM Maher, MD Mayes, G Raghu, M Girard… - 2019 - Eur Respiratory Soc
Background: In the SENSCIS trial, nintedanib reduced the progression of SSc-ILD vs placebo,
with an adverse event (AE) profile comparable to IPF. Aim: To evaluate dose adjustments …
with an adverse event (AE) profile comparable to IPF. Aim: To evaluate dose adjustments …
[CITATION][C] Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: Results of two 52-week, phase III, randomized, placebo-controlled trials …
…, M Selman, H Taniguchi, M Brun, M Girard… - A95. SKYFALL: LATE …, 2014 - atsjournals.org
Rationale: platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor
receptor (FGFR), is in clinical development as a treatment for idiopathic pulmonary fibrosis (IPF). …
receptor (FGFR), is in clinical development as a treatment for idiopathic pulmonary fibrosis (IPF). …
OP0242 SAFETY PROFILE OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC …
…, A Fischer, M Mayes, G Raghu, W Sauter, M Girard… - 2019 - ard.bmj.com
Background Nintedanib has been investigated in patients with systemic sclerosis-associated
interstitial lung disease (SSc-ILD) in the SENSCIS trial and idiopathic pulmonary fibrosis (…
interstitial lung disease (SSc-ILD) in the SENSCIS trial and idiopathic pulmonary fibrosis (…